Strongbridge Biopharma PLC | Mutual Funds
Mutual Funds that own Strongbridge Biopharma PLC
Tredje AP Fonden
909,581
1.95%
0
0.01%
06/30/2017
iShares Nasdaq Biotechnology ETF
518,258
1.11%
-6,783
0.03%
09/06/2018
Zacks Small Cap Core Fund
178,284
0.38%
-4,450
0.55%
02/28/2018
CREF Stock Account
114,113
0.24%
61,318
0%
03/31/2018
ALPS Medical Breakthroughs ETF
82,973
0.18%
0
0.16%
09/07/2018
Fidelity Spartan Small Cap Index Fund
59,394
0.13%
10,761
0.01%
04/30/2018
AXA 2000 Managed Volatility Portfolio
41,279
0.09%
10,851
0.01%
03/31/2018
Fidelity Nasdaq Composite Index
37,467
0.08%
0
0%
07/31/2018
TIAA-CREF Small Cap Blend Index Fund
34,264
0.07%
0
0.01%
05/31/2018
Lincoln VIP - SSgA Small Cap Index Fund
33,040
0.07%
18,700
0.01%
03/31/2018
| Address |
900 Northbrook Drive
Lower Southampton Pennsylvania 19053
United States
|
|
Employees
|
- |
| Website |
http://www.strongbridgebio.com |
| Updated |
07/08/2019 |
| Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA. |
